Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-09-21 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物关于2022年度以简易程序向特定对象发行A股股票发行结果暨股本变动的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the issuance of A shares to specific investors by the company 前沿生物药业（南京）股份有限公司. It includes information on the number of shares issued, pricing, subscription details, regulatory approvals, shareholding changes before and after issuance, and the impact on company control and management. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a comprehensive disclosure about a capital raising event involving share issuance to specific parties, including detailed procedural and regulatory compliance information. This fits the definition of a Capital/Financing Update (CAP). The document length and detail support a high confidence classification as CAP.
2022-09-21 Chinese
前沿生物关于召开2022年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 half-year performance explanation meeting (业绩说明会) for investors. It mentions the date, time, location, and participation method for the meeting, which is a form of investor presentation or earnings call. The document does not contain actual financial statements or detailed financial analysis but rather informs investors about the upcoming event where such information will be discussed. The document length is short (1484 characters), and it serves as a notice for an investor presentation rather than the presentation itself or a financial report. Therefore, the most appropriate classification is Investor Presentation (IP).
2022-09-18 Chinese
前沿生物自愿披露关于雾化吸入用FB2001药品注册临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a company regarding the acceptance of a clinical trial application for a drug by the National Medical Products Administration (国家药品监督管理局). It contains no financial data, no report or financial statements, and is primarily an announcement of regulatory approval related to drug development. The document length is short (1196 characters), and it is an announcement rather than a report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any financial filings. It is a regulatory announcement about clinical trial acceptance, which fits best under Regulatory Filings (RNS).
2022-09-13 Chinese
前沿生物关于签署募集资金专户存储三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the signing of a tripartite supervision agreement for the special account storing raised funds from a specific share issuance. It details the amount raised, the regulatory approval, the opening of special accounts for the raised funds, and the terms of the supervision agreement involving the company, banks, and the sponsor institution. There are no financial statements, earnings data, or management discussion of results. The document is a formal announcement about the fundraising and the regulatory compliance related to the raised funds management. This fits the category of Capital/Financing Update (CAP), as it concerns fundraising activities and capital management.
2022-09-09 Chinese
前沿生物自愿披露关于艾可宁在马来西亚获得药品上市注册批准的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a drug (艾可宁) for market registration in Malaysia. It includes details about the drug, its clinical trial results, and the company's plans for market promotion. The document is relatively short (1162 characters) and does not contain financial statements, detailed financial performance, or regulatory certifications. It is an announcement of a business development event rather than a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous company announcements that do not fit other specific categories.
2022-09-09 Chinese
毕马威华振会计师事务所（特殊普通合伙）关于前沿生物药业（南京）股份有限公司以简易程序向特定对象发行人民币普通股（A股）股票认购资金实收情况的验资报告
Regulatory Filings
2022-09-08 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.